Page last updated: 2024-11-12

narlaprevir

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

narlaprevir: an antiviral agent that inhibits hepatitis C virus NS3 protease [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

narlaprevir : An azabicyclohexane that is (1R,5S)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane substituted by [(3S)-1-(cyclopropylamino)-1,2-dioxoheptan-3-yl]aminoacyl and N-({1-[(tert-butylsulfonyl)methyl]cyclohexyl}carbamoyl)-3-methyl-L-valyl groups at positions 2S and 3, respectively. It is a hepatitis C virus (HCV) NS3/4A serine protease inhibitor (Ki = 6 nM) that is used for the treatment of chronic hepatitis C. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11857239
CHEMBL ID1255891
CHEBI ID173104
SCHEMBL ID583183
MeSH IDM0549797

Synonyms (41)

Synonym
HY-10300
sch-900518
arlansa
(1r,2s,5s)-3-{(2s)-2-[({1-[(tert-butylsulfonyl)methyl]cyclohexyl}carbamoyl)amino]-3,3-dimethylbutanoyl}-n-[(3s)-1-(cyclopropylamino)-1,2-dioxoheptan-3-yl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
CHEBI:173104
narlaprevir
(1r,2s,5s)-3-[n-({1-[(tert-butylsulfonyl)methyl]cyclohexyl}carbamoyl)-3-methyl-l-valyl]-n-[(3s)-1-(cyclopropylamino)-1,2-dioxoheptan-3-yl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
narlaprevirum
(1r,2s,5s)-n-[(3s)-1-(cyclopropylamino)-1,2-dioxoheptan-3-yl]-6,6-dimethyl-3-[3-methyl-n-({1-[(2-methylpropane-2-sulfonyl)methyl]cyclohexyl}carbamoyl)-l-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide
865466-24-6
sch900518
sch 900518
narlaprevir (usan/inn)
D09644
CHEMBL1255891
narlaprevir [usan:inn]
(1r,2s,5s)-n-((1s)-1-(2-(cyclopropylamino)-2-oxoacetyl)pentyl)-3-((2s)-2-(((1-(((1,1- dimethylethyl)sulfonyl)methyl)cyclohexyl)carbamoyl)amino)-3,3-dimethylbutanoyl)-6,6- dimethyl-3-azabicyclo(3.1.0)hexane-2-carboxamide
(1r,2s,5s)-3-(n-(((1-((tert-butylsulfonyl)methyl)cyclohexyl)amino)carbonyl)-3-methyl-l- valyl)-n-((1s)-1-((cyclopropylamino)(oxo)acetyl)pentyl)-6,6-dimethyl-3- azabicyclo(3.1.0)hexane-2-carboxamide
2857la2o07 ,
3-azabicyclo(3.1.0)hexane-2-carboxamide, n-((1s)-1-(2-(cyclopropylamino)-2- oxoacetyl)pentyl)-3-((2s)-2-((((1-(((1,1-dimethylethyl)sulfonyl)methyl)cyclohexyl) amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-, (1r,2s,5s)-
unii-2857la2o07
(1s,4s,5r)-3-[(2s)-2-[[1-(tert-butylsulfonylmethyl)cyclohexyl]carbamoylamino]-3,3-dimethyl-butanoyl]-n-[(1s)-1-[2-(cyclopropylamino)-2-oxo-acetyl]pentyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-4-carboxamide
CS-0445
narlaprevir [usan]
narlaprevir [inn]
narlaprevir [who-dd]
SCHEMBL583183
AKOS030526949
(3s)-n-cyclopropyl-3-{[(1r,2s,5s)-3-[(2s)-3,3-dimethyl-2-[({1-[(2-methylpropane-2-sulfonyl)methyl]cyclohexyl}carbamoyl)amino]butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2-yl]formamido}-2-oxoheptanamide
Q27254268
gtpl11572
F84170
MS-31189
(1r,2s,5s)-3-((s)-2-(3-(1-((tert-butylsulfonyl)methyl)cyclohexyl)ureido)-3,3-dimethylbutanoyl)-n-((s)-1-(cyclopropylamino)-1,2-dioxoheptan-3-yl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
TQP0852
NCGC00378650-01
EX-A5389
bdbm50537558
A916277
(1r,2s,5s)-3-[(2s)-2-[[1-(tert-butylsulfonylmethyl)cyclohexyl]carbamoylamino]-3,3-dimethylbutanoyl]-n-[(3s)-1-(cyclopropylamino)-1,2-dioxoheptan-3-yl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
DTXSID801025746

Research Excerpts

Overview

Narlaprevir (SCH 900518) is a potent inhibitor of the hepatitis C virus (HCV) nonstructural protein 3 serine protease that is primarily metabolized by the cytochrome P450-3A4 system.

ExcerptReferenceRelevance
"Narlaprevir is a novel NS3/4A protease inhibitor of hepatitis C virus (HCV), and it has been tested in a phase II clinical trial recently. "( Computational study on the molecular mechanisms of drug resistance of Narlaprevir due to V36M, R155K, V36M+R155K, T54A, and A156T mutations of HCV NS3/4A protease.
Chen, BZ; Geng, L; Ji, M; Wang, H, 2014
)
2.08
"Narlaprevir (SCH 900518) is a potent inhibitor of the hepatitis C virus (HCV) nonstructural protein 3 serine protease that is primarily metabolized by the cytochrome P450-3A4 system. "( Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients.
Bergmann, JF; de Bruijne, J; de Knegt, RJ; Hughes, EA; Janssen, HL; Li, J; Molenkamp, R; Reesink, HW; Schinkel, J; Tong, X; Treitel, MA; van Lier, JJ; van Vliet, AA; Weegink, CJ, 2010
)
2.12

Treatment

ExcerptReferenceRelevance
"Narlaprevir retreatment resulted in a 2.58 and 5.06 log10 IU/mL viral load decline in patients with and without mutations, respectively (P=<0.01)."( Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor.
Bergmann, JF; de Bruijne, J; de Knegt, RJ; Hughes, E; Janssen, HL; Molenkamp, R; Rebers, SP; Reesink, HW; Schinkel, J; Thomas, XV; Treitel, MA; Weegink, CJ, 2013
)
1.33

Toxicity

ExcerptReferenceRelevance
" Adverse events (AEs) were found in less than one half of patients (45 patients, or 42."( [Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C].
Batskikh, SN; Burnevich, EZ; Chulanov, VP; Gusev, DA; Kizlo, SN; Klimova, EA; Krasavina, EN; Mamonova, NA; Samsonov, MY; Tarkhova, EP; Yushchuk, ND; Znoyko, OO, 2019
)
0.82
" This combination was found to be safe and well - tolerated."( [Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C].
Batskikh, SN; Burnevich, EZ; Chulanov, VP; Gusev, DA; Kizlo, SN; Klimova, EA; Krasavina, EN; Mamonova, NA; Samsonov, MY; Tarkhova, EP; Yushchuk, ND; Znoyko, OO, 2019
)
0.82

Compound-Compound Interactions

ExcerptReferenceRelevance
" In period 2, after a 4-week washout, the same dose and regimen of narlaprevir was administered in combination with PEG-IFN-α-2b for 14 days."( Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients.
Bergmann, JF; de Bruijne, J; de Knegt, RJ; Hughes, EA; Janssen, HL; Li, J; Molenkamp, R; Reesink, HW; Schinkel, J; Tong, X; Treitel, MA; van Lier, JJ; van Vliet, AA; Weegink, CJ, 2010
)
0.91

Bioavailability

ExcerptReferenceRelevance
"Determination of the pharmacokinetics and absolute bioavailability of an experimental compound, SCH 900518, following a 89."( Precision and accuracy in the quantitative analysis of biological samples by accelerator mass spectrometry: application in microdose absolute bioavailability studies.
Arjomand, A; Chowdhury, SK; Gao, L; Hesk, D; Kasserra, C; Li, J; Song, Q, 2011
)
0.37

Dosage Studied

ExcerptRelevanceReference
"1 years after narlaprevir dosing in two patients in 5% and 45% of the viral population."( Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor.
Bergmann, JF; de Bruijne, J; de Knegt, RJ; Hughes, E; Janssen, HL; Molenkamp, R; Rebers, SP; Reesink, HW; Schinkel, J; Thomas, XV; Treitel, MA; Weegink, CJ, 2013
)
0.97
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
hepatitis C protease inhibitorAn inhibitor of hepatitis C protease, an enzyme required for production of proteins needed for viral assembly.
antiviral drugA substance used in the prophylaxis or therapy of virus diseases.
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitorAn EC 3.4.22.* (cysteine endopeptidase) inhibitor that interferes with the action of SARS coronavirus main proteinase (EC 3.4.22.69).
anticoronaviral agentAny antiviral agent which inhibits the activity of coronaviruses.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (7)

ClassDescription
sulfoneAn organosulfur compound having the structure RS(=O)2R (R =/= H).
ureas
tertiary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with a secondary amine; formula RC(=O)NHR(1)R(2).
azabicyclohexane
pyrrolidinecarboxamide
secondary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1).
cyclopropanesCyclopropane and its derivatives formed by substitution.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Genome polyprotein Ki0.00600.00000.00670.0300AID1645923
Non-structural protein 4A Ki0.00600.00000.00670.0300AID1645923
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)5.72900.00022.45859.9600AID1845236
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (37)

Assay IDTitleYearJournalArticle
AID1845236Inhibition of SARS-CoV-2 MPro2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
AID518712Antiviral activity against Hepatitis C virus genotype 1b assessed as log reduction in RNA level at 5 times EC90 after 14 days by RT-PCR method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID518713Antiviral activity against Hepatitis C virus genotype 1b assessed as log reduction in RNA level at 1.2 times EC90 after 14 days by RT-PCR method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID518722Inhibition of Hepatitis C virus genotype 1b NS3 protease2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID518716Inhibition of Hepatitis C virus genotype 1a NS3 protease2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID518720Resistance index, ratio of EC90 for Hepatitis C virus genotype 1b expressing NS3 protease A156T/V mutant to EC90 for wild type Hepatitis C virus genotype 1b after 3 days by RT-PCR method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID518708Ratio of Ki for boceprevir-resistant Hepatitis C virus genotype 1b NS3 protease T54A mutant to Ki for Hepatitis C virus genotype 1b NS3 protease2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID518718Resistance index, ratio of EC90 for Hepatitis C virus genotype 1b expressing NS3 protease T54A/S mutant to EC90 for wild type Hepatitis C virus genotype 1b after 3 days by RT-PCR method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID518717Inhibition of Hepatitis C virus genotype 2a NS3 protease2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID518703Ratio of Ki for boceprevir-resistant Hepatitis C virus genotype 1b NS3 protease A156T mutant to Ki for Hepatitis C virus genotype 1b NS3 protease2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID518710Cytotoxicity against human HuH7 cells by MTS assay2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID1645924Antiviral activity against HCV2019European journal of medicinal chemistry, Feb-15, Volume: 164A review on HCV inhibitors: Significance of non-structural polyproteins.
AID518532Resistance index, ratio of EC50 for boceprevir-resistant Hepatitis C virus genotype 1b expressing NS3 protease V36M and R155K mutant to EC50 for wild type Hepatitis C virus genotype 1b after 3 days by RT-PCR method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID518528Resistance index, ratio of EC50 for boceprevir-resistant Hepatitis C virus genotype 1b expressing NS3 protease V36M mutant to EC50 for wild type Hepatitis C virus genotype 1b after 3 days by RT-PCR method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID518714Antiviral activity against Hepatitis C virus genotype 1b assessed as decrease in RNA level after 3 days by RT-PCR method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID518715Inhibition of Hepatitis C virus genotype 3a NS3 protease2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID518704Ratio of Ki for boceprevir-resistant Hepatitis C virus genotype 1b NS3 protease A156S mutant to Ki for Hepatitis C virus genotype 1b NS3 protease2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID1645923Inhibition of HCV NS3/4a protease using Ac-DE-Dap(QXL520)-EE-Abu-shi-[COO]AS-C(5-FAMsp)-NH2 as substrate after 15 mins2019European journal of medicinal chemistry, Feb-15, Volume: 164A review on HCV inhibitors: Significance of non-structural polyproteins.
AID518706Ratio of Ki for boceprevir-resistant Hepatitis C virus genotype 1b NS3 protease T54S mutant to Ki for Hepatitis C virus genotype 1b NS3 protease2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID518530Ratio of Ki for boceprevir-resistant Hepatitis C virus genotype 1b NS3 protease V36M and R155K double-mutant to Ki for Hepatitis C virus genotype 1b NS3 protease2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID518527Resistance index, ratio of EC50 for boceprevir-resistant Hepatitis C virus genotype 1b expressing NS3 protease T54A mutant to EC50 for wild type Hepatitis C virus genotype 1b after 3 days by RT-PCR method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID518526Ratio of Ki for boceprevir-resistant Hepatitis C virus genotype 1b NS3 protease D168V mutant to Ki for Hepatitis C virus genotype 1b NS3 protease2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID518533Resistance index, ratio of EC50 for boceprevir-resistant Hepatitis C virus genotype 1b expressing NS3 protease V170A mutant to EC50 for wild type Hepatitis C virus genotype 1b after 3 days by RT-PCR method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID518705Ratio of Ki for boceprevir-resistant Hepatitis C virus genotype 1b NS3 protease R155K mutant to Ki for Hepatitis C virus genotype 1b NS3 protease2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID518531Ratio of Ki for boceprevir-resistant Hepatitis C virus genotype 1b NS3 protease T54S and R155K double-mutant to Ki for Hepatitis C virus genotype 1b NS3 protease2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID518524Resistance index, ratio of EC50 for boceprevir-resistant Hepatitis C virus genotype 1b expressing NS3 protease A156S mutant to EC50 for wild type Hepatitis C virus genotype 1b after 3 days by RT-PCR method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID518721Resistance index, ratio of EC90 for Hepatitis C virus genotype 1b expressing NS3 protease T54A and A156T mutant to EC90 for wild type Hepatitis C virus genotype 1b after 3 days by RT-PCR method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID518525Resistance index, ratio of EC50 for boceprevir-resistant Hepatitis C virus genotype 1b expressing NS3 protease R155K mutant to EC50 for wild type Hepatitis C virus genotype 1b after 3 days by RT-PCR method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID518702Resistance index, ratio of EC50 for boceprevir-resistant Hepatitis C virus genotype 1b expressing NS3 protease A156T mutant to EC50 for wild type Hepatitis C virus genotype 1b after 3 days by RT-PCR method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID518701Resistance index, ratio of EC50 for boceprevir-resistant Hepatitis C virus genotype 1b expressing NS3 protease D168V mutant to EC50 for wild type Hepatitis C virus genotype 1b after 3 days by RT-PCR method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID518707Ratio of Ki for boceprevir-resistant Hepatitis C virus genotype 1b NS3 protease F43C mutant to Ki for Hepatitis C virus genotype 1b NS3 protease2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID518711Ratio of Ki for boceprevir-resistant Hepatitis C virus genotype 1b NS3 protease V36M mutant to Ki for Hepatitis C virus genotype 1b NS3 protease2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID518719Resistance index, ratio of EC90 for Hepatitis C virus genotype 1b expressing NS3 protease A156S mutant to EC90 for wild type Hepatitis C virus genotype 1b after 3 days by RT-PCR method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID518709Ratio of Ki for boceprevir-resistant Hepatitis C virus genotype 1b NS3 protease V36A mutant to Ki for Hepatitis C virus genotype 1b NS3 protease2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID518529Ratio of Ki for boceprevir-resistant Hepatitis C virus genotype 1b NS3 protease V170A mutant to Ki for Hepatitis C virus genotype 1b NS3 protease2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's11 (73.33)24.3611
2020's4 (26.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.87 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index5.22 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (26.67%)5.53%
Reviews2 (13.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (60.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]